<DOC>
	<DOC>NCT00612196</DOC>
	<brief_summary>Dose escalation study to assess the safety and tolerability of TB-402, a monoclonal antibody directed against FVIII, versus placebo in healthy male volunteers.</brief_summary>
	<brief_title>A Phase I Study of Monoclonal Antibody TB-402 in Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Antibodies</mesh_term>
	<criteria>Males 18 to 45 (Groups 19) or 55 to 75 (Group 10) years of age No clinically important abnormal physical, laboratory, ECG findings Normal (or abnormal but ncs) supine blood pressure (BP) and heart rate (HR) Self or family history of cardiovascular or pulmonary disorder, coagulation or bleeding disorders or reasonable suspicion of vascular malformations eg cerebral haemorrhage, aneurysm or premature stroke. Any autoimmune disease. Previous allergic reaction to immunoglobulin. Present, or history of, severe allergy, for example asthma or anaphylactic reactions or allergy requiring treatment. Consumption of aspirin, other nonsteroidal antiinflammatory drugs or other drugs known to affect platelet function or any other aspect of coagulation within 14 days before drug administration. Abnormal platelet function or clinically significant out of range values for any coagulation tests. History of important bleeding episodes eg haematemesis, rectal bleeding, severe or recurrent epistaxis, haemoptysis, haematuria or intracranial haemorrhage. Screening FVIII:C &lt; 50%.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Safety and tolerability</keyword>
</DOC>